Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sanara MedTech Inc (SMTI) Fair Value & Analysis

Healthcare · US · Market cap $199M

Price$21.75
Fair Value$10.30
Upside-52.6%
Quality95/100
Evidence: High Range $9.27 – $17.76

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sanara MedTech Inc (SMTI) currently trades at $21.75, while our model-based Fair Value estimate is $10.30 — implying the stock looks roughly 52.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -60% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -38% Medline Inc (MDLN) -16% Becton, Dickinson and Company (BDX) -26% Alcon Inc (ALC) -32%

Frequently asked questions

Is Sanara MedTech Inc (SMTI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $10.30 versus a price of $21.75 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SMTI?
Our 21-model fair value for Sanara MedTech Inc is $10.30 (as of Jun 24, 2026), built from audited fundamentals. The current price is $21.75.
What is the quality score of SMTI?
Sanara MedTech Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.